

4DMedical granted Authority to Operate at Harry S. Truman VA

18 May 2023

Highlights

- 4DMedical granted Authority to Operate (ATO) at Harry S. Truman Memorial Veterans Hospital
 - ATO allows 4DMedical to deliver automated scans through its SaaS platform
 - Important milestone on the path to gaining National ATO at the VA
-

Melbourne, Australia, 18 May 2023: Respiratory imaging technology company, 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) is pleased to announce that following the successful completion of the first XV LVAS® scan at Harry S. Truman Memorial Veterans Hospital, the Company has now been granted Authority to Operate for XV LVAS® at this site.

Authority to Operate (ATO)

To ensure the security and privacy of the vast amount of sensitive and personal health information that the Veterans Health Administration (VA) is responsible for, the VA has comprehensive controls and guidelines that govern the operation of information systems within its network. Before a system can be deployed or connected to the VA network it must undergo a rigorous assessment and authorisation process. The ATO is formal authorisation granted to an information system or technology infrastructure to operate within the VA's network.

As a SaaS vendor to the VA, 4DMedical requires ATO at each VA site where it seeks to deliver scans at scale through its fully automated SaaS platform. This first ATO is an important milestone for the Company as it demonstrates the robust and secure nature of 4DMedical's platform. Additionally, once 4DMedical has ATO at two sites, it is eligible to apply for a National ATO, which will provide the Company with authorisation at all 171 major clinical centres within the VA network.

The ATO with Harry S. Truman Hospital demonstrates further validation of 4DMedical's bottom-up approach to VA engagement, and the Company is utilising this success as a template to advance progress at other VA sites.

4DMedical Founder and CEO Andreas Fouras said:

The VA IT authorisation process has been the core source of friction and delay at Truman and other VA sites. This ATO has been hard fought, but we now feel confident that we are in position to expand on this success. I am excited by the prospect of National ATO, which will accelerate our top-down efforts to deliver our technology across the VA. I feel strongly that XV Technology® is the best way to provide every Veteran with access to rich information on the effects of toxic exposures on their lungs, without the burden of an expensive and invasive biopsy, and today's announcement takes us one step closer to this prospect.

—ENDS—

Authorised by the 4DMedical CEO.



Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.